Group One Trading’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Group One Trading's RNA Position: Q3 2026 in Review
Group One Trading reduced its Atrium Therapeutics (RNA) stake by 98% in Q3 2026, selling an estimated $41.2K and leaving 85 shares worth $704. The position accounts for ﹤0.01% of the portfolio, ranked #7213.
Group One Trading first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $49.2K in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Group One Trading held 85 shares of Atrium Therapeutics worth $704 as of Q3 2026.
- Group One Trading sold 3,490 Atrium Therapeutics shares in Q3 2026, an estimated $41.2K.
- Atrium Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #7213 holding.
- Group One Trading first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Group One Trading's Atrium Therapeutics position peaked at $49.2K in Q1 2026.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.